-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1663 Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Maria Carmen Martinez Munoz, MD, PhD1*, Irma Khvedelidze2*, Mathilde Fekom3*, Benedicte Deau Fischer, MD4*, Amira Marouf5*, Herve Ghesquieres, MD, PhD6*, Luc-Matthieu Fornecker, MD, PhD7*, Francesco Merli8*, Piero Maria Stefani, MD9*, Fulvio Massaro10*, Barbara Botto11*, A. Burhan Ferhanoglu, MD12, Olga Meltem Akay13*, Murat Ozbalak, MD14*, Manuel Espeso De Haro15*, Samuel Romero, MD16*, Jaques-Emmanuel Galimard17*, Bertram Glass, MD18*, Ali Bazarbachi, MD, PhD19 and Anna Sureda Balari20

1Hematopoietic Cell Transplant Unit, Hospital Clinic of Barcelona, ICAMS, Barcelona, Spain
2EBMT Paris Study Unit, Paris, France
3European Bone Marrow Transplantation Lymphoma Working Party, Paris, France
4Department of Hematology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, FRA
5INSERM UMR U1163—Imagine Institute, Paris, France
6Department of Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France
7Institut De Cancérologie Strasbourg Europe, Hematology Department, Strasbourg, France
8Hematology Department, AZIENDA USL-IRCCS DI REGGIO EMILIA, Reggio Emilia, Italy
9Struttura Complessa di Ematologia Dipartimento Strutturale di Medicina Interna, Presidio Ospedaliero di Treviso AULSS2 Marca Trevigiana, Treviso, Italy
10Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium
11Division of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy
12Koç University Medical Faculty, Istanbul, Turkey
13Koç University Medical Faculty, Istambul, Turkey
14Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
15Hospital Regional Universitario de Málaga, MALAGA, Spain
16Hematology Research Group, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
17EBMT Lymphoma Working Party, Paris, France
18Department of Hematology and Stem Cell Transplantation, Helios Klinikum Berlin-Buch, Berlin, Germany
19American University of Beirut Dept. of Medicine, Beirut, Lebanon
20Instituto Catalán de Oncología - Hospital Duran i Reynals, Barcelona, Spain

Introduction: Maintenance therapy with brentuximab vedotin (BV) after autologous stem cell transplantation (ASCT) improved progression-free survival (PFS) among high-risk patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) in the phase III AETHERA trial. However, since the trial, HL treatment has evolved, often incorporating BV earlier in therapy, potentially affecting BV maintenance efficacy post-ASCT.

Methods: Information of patients with R/R HL who received BV as maintenance after first ASCT between May 2016 and January 2021 was obtained from GELTAMO, FIL, LYSARC, and Turkish Lymphoma Group databases and reported to EBMT registry. The decision to use BV consolidation was made by the attending physician on an individual basis. Patients who received BV for disease relapse after ASCT were excluded from the study. The primary endpoint was 2-year PFS from ASCT.

Results: A total of 362 patients (female 46%/male 54%) with HL met the inclusion criteria. The median age at ASCT was 31y (14-69). Among them, 159 patients (44%) had primary refractory disease, 181 (50%) relapsed within 12 months of frontline therapy, 119 (34%) had extranodal disease at relapse, 13 (8%) had bulky disease at relapse, and 50 (21%) had B symptoms at relapse. Fifty-one percent of the patients received only 1 salvage therapy before ASCT, 36% 2 lines, 12% >3, and 1% proceeded to transplant without additional treatment. A total of 187 patients (52%) received BV before ASCT; of these, 8% received BV alone and 56% received it in combination with chemotherapy (36% unknown). At the time of ASCT, 247 (72%) patients were in complete remission (CR), 72 (21%) in partial remission (PR), and 23 (7%) had refractory disease or stable disease. Median time from ASCT to BV initiation was 2.1 months (IQR 1.5-2.9). The median number of BV maintenance cycles was 12 (IQR 8-16). Twenty-seven percent of patients stopped BV maintenance due to toxicity, and 22% due to HL relapse/progression.

After a median follow-up of 2.5 years (2.2-2.6), the 2 and 5-year overall survival (OS) rates were 93.9% (95% CI 90.7-96) and 85% (95% CI 76.5-90.6), respectively, while the PFS rates were 78.1% (95% CI 73-82.4) and 69.4% (95% CI 58.6-78), respectively. In univariate analysis, relapse within 12 months of frontline therapy (HR 2.6, 95% CI 1.16-5.85, P=0.021), receiving >2 salvage therapy lines (HR 2.47, 95% CI 1.13-5.41, P=0.023), and non-CR at ASCT (HR 3.76, 95% CI 1.79-7.88, P<0.001) were associated with worse OS. Patients who had primary refractory HL (HR 1.97, 95% CI 1.24-3.13, P=0.004), and those with non-CR at ASCT (HR 3.91, 95% CI 2.42-6.33, P<0.001) had significantly lower PFS. Patients treated with BV before transplant had better 2-year OS (97.8% vs. 89.8%, HR 0.39, 95% CI 0.18-0.86, P=0.019) and 2-year PFS (83.7% vs. 72.6%, HR 0.56, 95% CI 0.35-0.9, P=0.017) than those who did not receive it. The multivariate analysis demonstrated that the only variables with a significant impact on OS were disease status at ASCT (HR 3.4, 95% CI 1.57-7.39, P=0.002) and BV treatment prior to ASCT (HR 0.41, 95% CI 0.18-0.95, P=0.037). Similarly, these two variables were the only factors significantly correlated with the PFS outcomes (HR 3.42, 95% CI 2.08-5.62, P<0.001; and HR 0.59, 95% CI 0.35-0.99, P=0.044, respectively). The aforementioned factors did not affect non-relapse mortality. Conversely, non-CR status was correlated with an elevated risk of HL relapse (HR 3.72, 95% CI 2.23-6.21, P<0.001), while BV treatment before ASCT was linked to a reduced relapse risk (HR 0.56, 95% CI 0.33-0.97, P=0.037).

Conclusions: This large EBMT-registry study shows that in patients with high-risk R/R HL receiving BV maintenance after ASCT, the factors associated with better PFS were achieving a CR before ASCT and being treated with BV before transplantation. The excellent PFS in the group of patients previously exposed to BV indicates a clear benefit of including this drug in salvage regimens prior to ASCT.

Disclosures: Martinez Munoz: Novartis: Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees. Ghesquieres: Gilead, Roche, BMS, Abbvie, Takeda: Honoraria; Roche, BMS, Takeda: Consultancy. Stefani: Takeda: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees. Botto: TAKEDA: Speakers Bureau. Espeso De Haro: Pfizer: Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Kite: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. Romero: Kyowa Kirin: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Kite: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees. Glass: Sobie: Consultancy; Miltenyi: Consultancy; Abbvie: Consultancy; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; JAZZ: Honoraria. Bazarbachi: Caribou: Honoraria; Amgen: Honoraria; Jansen: Honoraria, Research Funding; Biologix: Research Funding; Takeda: Honoraria; Pfizer: Research Funding; Roche: Honoraria, Research Funding. Sureda Balari: Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Honoraria; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH